Grade My Investments
HomeFree Stock Grades › ADMA

ADMA Biologics, Inc. (ADMA) Stock Grade

ADMA · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$4.3B
P/E Ratio
29.6
Revenue Growth (YoY)
+19.6%
Net Margin
28.8%
Return on Equity
30.8%
Dividend Yield
None

About ADMA Biologics, Inc.'s fundamentals

ADMA Biologics is a biotechnology company with a market capitalization of $4.3 billion, currently trading at a P/E ratio of 29.6 times earnings. The company demonstrated solid operational performance with 19.6% year-over-year revenue growth and a strong net margin of 28.8%, indicating efficient conversion of sales to profit. Return on equity stands at 30.8%, reflecting effective deployment of shareholder capital, while the company does not currently pay a dividend.

Track ADMA free — no credit card required. Live grade + monthly AI report →